Data from novel Hedgehog pathway inhibitor program to be presented at upcoming conferences

-- Julian Adams, Ph.D., President of R&D and CSO, to Present at New York City Academy of Sciences' "Hedgehog Pathway in Cancer" Symposium --

-- Infinity Scientists Also to Discuss Hedgehog Pathway and Data at Biorbis Cancer Stem Cells Meeting and EMBO Workshop on Hedgehog Signaling --

Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that members of its senior leadership and scientific teams will be leading discussions and presenting data from its novel Hedgehog pathway inhibitor program – an emerging area of cancer research – at several upcoming conferences. Infinity's Hedgehog pathway inhibitor, IPI-926, is a potent, orally-delivered small molecule drug candidate that has demonstrated significant anti-tumor activity in multiple preclinical cancer models and in settings where the malignant activation of the pathway is implicated in difficult-to-treat cancers. IPI-926 is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors. Data from this trial are expected to be presented in 2010, and Infinity anticipates initiating Phase 2 development with IPI-926 later this year.

The upcoming conferences where Infinity's insights into the Hedgehog pathway and IPI-926 will be discussed include:

New York Academy of Sciences "Hedgehog Pathway in Cancer" Symposium - March 17, 2010, New York City

• Julian Adams, Ph.D., president of research and development and chief scientific officer, will discuss the emerging role of Hedgehog pathway inhibition in treating cancer and its novel approach with IPI-926. 

Biorbis Cancer Stem Cells - March 24-25, 2010, Cambridge, Massachusetts

• Vito Palombella, Ph.D., vice president of drug discovery, will present an overview of the preclinical and clinical development of IPI-926 on March 25, 2010. 

European Molecular Biology Organization (EMBO) Workshop on Hedgehog Signaling - March 27-31, 2010, St. Jean Cap Ferrat, France

• Karen McGovern, Ph.D., director of cancer biology, will discuss the discovery and characterization of IPI-926 in tumor models in an oral and poster presentation on March 31, 2010. 

"We look forward to joining our industry colleagues for these Hedgehog pathway focused sessions and discussing the critical role it is playing in the development of a new generation of cancer treatments," stated Dr. Adams. "Infinity sees significant promise and potential in Hedgehog pathway inhibition, and has approached drug discovery and development in this space with tremendous tenacity. We believe our approach with IPI-926 could result in a targeted, personalized treatment that is able to address a broad range of cancers, including some of the most difficult to treat cancers. We are committed to this field to make a meaningful difference in patients' lives."